Multiple complications of uncontrolled type 1 diabetes mellitus

• Nina G. Ostanina
• Elena K. Serezhina
• Andrey G. Obrezan
• Valeria M. Olesova

Abstract

Patients with type 1 diabetes mellitus (DM), unlike patients with type 2 DM, have an earlier age of the pathology onset and by the age of 40 have a long history of the disease with the development of micro- and macrovascular complications. It should be noted that chronic kidney disease (CKD) is registered in 30–40% of such patients. Type 1 DM is accompanied by persistent microalbuminuria, transient microalbuminuria, and macroalbuminuria, the risk of cardiovascular events increases. Therefore, patients with type 1 DM and CKD, regardless of their age, need more thorough and early (compared with patients with type 2 DM) screening of cardiovascular diseases in general (including chronic heart failure). The clinical case we have cited confirms the above.

Keywords:type 1 diabetes mellitus; chronic kidney disease; nephropathy; polyneuropathy; edematous ascitic syndrome; chronic heart failure

References

1. Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A., Sazonova D.V., et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Sakharniy diabet [Diabetes Mellitus]. 2023; 26 (2): 104–23. DOI: https://doi.org/10.14341/DM13035 (in Russian)

2. Evloeva M.I., Arutyunova M.S., Severina A.S., Trubitsyna N.P., Zaytseva N.V., Shamkhalova M.S., et al. Chronic kidney disease in patients with long-term type 1 diabetes mellitus. Sakharniy diabet [Diabetes Mellitus]. 2023; 26 (6): 504–14. DOI: https://doi.org/10.14341/DM13108 (in Russian)

3. Costacou T., Orchard T.J. Cumulative kidney complication risk by 50 years of type 1 diabetes: the effects of sex, age, and calendar year at onset. Diabetes Care. 2018; 41 (3): 426–33.

4. Shamkhalova M.S., Vikulova O.K., Zheleznyakova A.V., Isakov M.A., Shestakova M.V., Dedov I.I., et al. Trends in the epidemiology of chronic kidney disease in patients with diabetes in Russian Federation according to the Federal diabetes register (2010–2022). Sakharniy diabet [Diabetes Mellitus]. 2023; 26 (5): 404–17. DOI: https://doi.org/10.14341/DM13090 (in Russian)

5. Sun J., Wang C., Zhao M., et al. Childhood diabetes mellitus and early-onset kidney diseases later in life: a nationwide population-based matched cohort study. BMC Med. 2022; 20 (1): 428.

6. de Boer I.H., Khunti R., Sadusky T., et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022; 102 (5): 974–89.

7. Toppe C., Mollsten A., Waernbaum I., et al. Decreasing cumulative incidence of end-stage renal disease in young patients with type 1 diabetes in Sweden: a 38-year prospective nationwide study. Diabetes Care. 2019; 42 (1): 27–31.

8. de Boer I.H., Gao X., Cleary P.A., et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT/EDIC study. Clin J Am Soc Nephol. 2016; 11 (11): 1969–77.

9. Vikulova O.K., Elfimova A.R., Zheleznyakova A.V., Isakov M.А., Shamkhalova M.S., Shestakova M.V., Mokrysheva N.G. Chronic kidney disease risk calculator: new possibilities for predicting pathology in patients with diabetes mellitus. Consillium Medicum. 2022; 24 (4): 224–33. (in Russian)

10. Perkins B.A., Bebu I., de Boer I.H., et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Risk factors for kidney disease in type 1 diabetes. Diabetes Care. 2019; 42 (5): 883–90.

11. Biester T., Aschemeier B., Fath M., et al. Effects of dapagliflozin on insulin-requirement, glucose excretion, and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth type 1 diabetes. Diabetes Obes Metab. 2017; 19 (11): 1635–9. DOI: https://doi.org/10.1111/dom.12975

12. Henry R., Rosenstock J., Edelman S., et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes; a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015; 38 (3): 412–9.

13. Tamez H., Garza L., et al. Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus. J Diabetes Metab Disord. 2015; 14: 78.

14. Groop P.H., Danona P., Phillip M., Gillard P., Edelman S., et al. Effect dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomized controlled trials. Lancet Diabetes Endocrinol. 2020; 8 (10): 845–54.

15. Yingying Y., Hui P., Bo W., et al. Efficacy and safety of SGL2 inhibitors in patients with type 1 diabetes: a meta-analysis of randomized controlled trials. Chin Med Sci. 2017; 32 (1): 22–4.

16. Rosenstock J., Marquard J., Laffel L., et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care. 2018; 41 (12): 2560–9.

17. Tucker M.E. FDA turns down sotagliflozin for type 1 diabetes [Electronic resource] // Medscape. 2019 March 22. URL: https://www.medscape.com/viewarticle/910851?form=fpf (date of access May 21, 2024).

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)